Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic Melanoma

Reinhard Dummer, Georgina V Long, Caroline Robert, Hussein A Tawbi, Keith T Flaherty, Paolo A Ascierto, Paul D Nathan, Piotr Rutkowski, Oleg Leonov, Caroline Dutriaux, Mario Mandalà, Paul Lorigan, Pier Francesco Ferrucci, Jean Jacques Grob, Nicolas Meyer, Helen Gogas, Daniil Stroyakovskiy, Ana Arance, Jan C Brase, Steven GreenTomas Haas, Aisha Masood, Eduard Gasal, Antoni Ribas, Dirk Schadendorf

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic Melanoma'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science